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rankings obtained from standard logistic regression (LR) relative to MLM mod-
eling of risk-adjusted hospital mortality rates for stroke among hospitals in the 
south. Methods: The 2012 U.S. Nationwide Inpatient Sample (NIS) was used 
to identify patients with a primary diagnosis for ischemic stroke, using ICD-9 
diagnosis criteria. Stepwise backward selection technique with logistic regres-
sion and multilevel modeling was performed to examine the variation among 
hospitals in the south by adjusting for patient-level and hospital-level risk factors. 
The analysis included hospitals with more than 30 stroke cases in the southern 
region of the U.S. The hospital IDs have been masked in order to comply with the 
NIS data user agreement. Results: There were 19,071 stroke hospitalizations in 
320 hospitals. The same rankings were observed for top performers in hospitals’ 
observed/expected ratios (O/E) by LR and MLM. However, high O/E outlier status 
differed between the two statistical methods, yielding different rankings for worst 
performance. Hospital K, L, M were ranked as the worst 3 performers in LR whereas 
K, N, L were ranked the same in MLM. O/Es of Hospital K were 4.49 (CI= 1.62-9.84) 
and 3.942 (CI= 1.42-8.64) in LR and MLM, respectively. O/E’s of Hospital L were 4.24 
(CI= 1.90-8.13) and 3.33 (CI= 0.70-9.54) in LR and MLM, respectively. LR identified 
Hospital M’s O/E ratio as 3.58 (1.47-7.26). MLM identified Hospital N’s O/E as 3.33 
(CI= 0.70-9.54). ConClusions: Although both logistic regression and multilevel 
modeling produced similar rankings for top performers, the MLM approach was 
more conservative in its O/E ratio estimates which were shrunken towards the 
overall mean. The MLM method is recommended to better statistically adjust and 
avoid false positive identification of outliers.
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objeCtives: Tools used to address confounding, such as measures of patient 
comorbidity, should preferably be validated prior to conducting health services 
and outcomes research using novel sources of administrative health data. Our 
objective was to validate and compare the predictive performance of two vari-
ants of the Elixhauser comorbidity measures for predicting all-cause, in-hospital 
mortality using Cerner Health Facts®, a large nationwide U.S. multi-payer elec-
tronic health record database. Methods: Quan et al. and the AHRQ version 3.7 
adaptations of the Elixhauser comorbidity measures were selected to estimate 
the comorbidity burden of Health Facts® inpatients, outpatients, and emergency 
care recipients aged 18 to 89 years from Jan. 2000 to Dec. 2012. Diagnoses identi-
fied one and two years preceding an index encounter were assessed in a group 
of unique patients. C-statistics obtained from forward stepwise multiple logistic 
regression fitted models and ROC curve differences were derived to compare the 
predictive performance of each variant/lookback period combination. Results: 
Of 8,128,713 patients with a mean age of 51.4 years and a male composition of 
41.6%, 76,235 (0.9%) were deceased at 1-year. Age, sex and all comorbidities were 
significantly correlated with mortality in the two Elixhauser variants irrespec-
tive of lookback period. Excellent predictive performance (c-statistic) was found 
for the Quan (c1yr= 0.874, c2yrs= 0.873) and AHRQ (c1yr= 0.871, c2yrs= 0.870) vari-
ants and both exceeded the baseline model (c= 0.803, P< .0001) limited to age and 
sex. The Quan variant performed slightly better than the AHRQ variant in both 
lookback periods. However, increasing the lookback period from 1 to 2 years did 
not improve predictive performance. ConClusions: Variants of the Elixhauser 
comorbidity measures were validated in Cerner Health Facts® and demonstrated 
excellent predictive performance for all-cause in-hospital mortality at one year. 
These results support the utility of Health Facts® as a novel and attractive source 
of data for administrative database research.
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objeCtives: Retrospective chart reviews are often used to generate real-world evi-
dence of patient outcomes. Physicians participating in these studies may be asked 
to randomly select patient charts for inclusion among all charts meeting eligibility 
criteria. Random selection is important for obtaining representative samples and 
unbiased estimates of patient outcomes. This study examined a statistical method 
for detecting non-random selection of patient charts with an application to real 
data. Methods: Example data were drawn from a recent retrospective oncology 
chart review study that estimated overall survival (OS) and progression-free survival 
(PFS) following the start of treatment. In the study, participating physicians were 
asked to provide a random sample of their eligible patients. Latent class analysis 
(LCA) was used to test whether the distribution of PFS and OS was consistent with 
random selection for all charts (a one class model) versus a mixture in which some 
physicians selected random charts and others selected non-random, convenient 
charts (models with > 1 class). The best fitting model was identified using infor-
mation criteria. Physician characteristics, PFS and OS were compared across latent 
classes. Results: In overall sample of charts, median durations of OS and PFS 
were significantly longer than published benchmarks drawn from randomized tri-
als. LCA identified evidence for two classes of physicians. One class was consistent 
with biased selection for recently seen patients who were still alive at the time 
of chart review, resulting in bias towards longer OS and PFS. The other class was 
consistent with random selection, and exhibited OS and PFS that were significantly 
closer to published benchmarks. ConClusions: In this example using data from 
a retrospective oncology chart review, LCA was helpful in identifying physicians 
who may have selected convenient but non-random patient charts. LCA warrants 
0.40), and 0.72 (0.50-0.90), respectively, but were stable over time (re-test). For data 
available in 2009, incidence of PML (cases per 100,000 patients) over two years was 
estimated at 0.22 (95% CI 0.00078–3.13) for patients initiated on efalizumab and 
1.21 (0.0052–14.81) for patients remaining on treatment. ORs versus placebo were 
1.7 (1.4–2.2) for AEs and 1.5 (0.6–5.1) for SAEs. Combination of normalized weights 
and scores yielded a safety estimate of efalizumab versus placebo in 2009 of -0.65 
(stdev 0.28) (on a scale of -1 to +1). The same approach was applied to compare 
efalizumab with three active comparators. ConClusions: The method supports 
comparative safety assessment and captures uncertainty in judgments and in data, 
allowing the inclusion of rare, disparate and newly emergent safety data in quan-
titative assessments.
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objeCtives: Utility estimates are important health outcomes for economic evalua-
tion of care and treatment interventions for patients with HIV/AIDS. We conducted 
a systematic review and meta-analysis of utility measurements to examine the 
performance of preference-based instruments, estimate health utility of patients 
with HIV/AIDS by disease stages, and investigate changes in their health utility over 
the course of antiretroviral treatment. Methods: We searched PubMed/Medline, 
Cochrane Database of Systematic Review, NHS Economic Evaluation Database and 
Web of Science for English-language peer-reviewed papers published during 2000-
2013. We selected 49 studies that used 3 direct and 6 indirect preference based 
instruments to make a total of 218 utility measurements. Random effect models 
with robust estimation of standard errors and multivariate fractional polynomial 
regression were used to obtain the pooled estimates of utility and model their 
trends. Results: Reliability of direct-preference measures tended to be lower than 
other types of measures. Utility elicited by two of the indirect preference meas-
ures - SF-6D (0.171) and EQ-5D (0.114), and that of Time-Trade off (TTO) (0.151) 
was significantly different than utility elicited by Standard Gamble (SG). Compared 
to asymptomatic HIV patients, symptomatic and AIDS patients reported a decre-
ment of 0.025 (p= 0.40) and 0.176 (p= 0.001) in utility scores, adjusting for method of 
assessment. In longitudinal studies, the pooled health utility of HIV/AIDS patients 
significantly decreased in the first 3 months of treatment, and rapidly increased 
afterwards. Magnitude of change varied depending on the method of assessment 
and length of antiretroviral treatment. ConClusions: The study provides an 
accumulation of evidence on measurement properties of health utility estimates 
that can help inform the selection of instruments for future studies. The pooled 
estimates of health utilities and their trends are useful in economic evaluation and 
policy modelling of HIV/AIDS treatment strategies.
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objeCtives: This study sought to compare and improve the methods for estimating 
input parameters to populate a decision-analytic Markov model for use in the health 
economic assessment of novel biomarkers for primary prevention of Cardiovascular 
Disease. Methods: An initial five-state Markov model is built using the FINRISK97 
cohort and follow-up for coronary and stroke events. Two different approaches to 
estimate the transition rates between health states are used. The first approach 
involves a separate analysis for each of the transitions between different health 
states each using a separate Cox Proportional Hazards model (censoring any move-
ments outside the health states of interest). In the second approach, all the transi-
tions are examined in one process using the R package ‘msm’ to maximize the 
overall likelihood expression. Results: The first approach requires considerable 
data manipulation to account for the censoring in each separate analysis; however 
convergence of results is less problematic. While msm considers the overall likeli-
hood expression, it has difficulty fitting a five-state model due to the number of 
parameters which need estimated. Two recommendations from this research for 
using msm include building the model iteratively, adding covariates one step at a 
time. For example to build the model with age plus one covariate, the baseline tran-
sition matrix and regression coefficients from the age only model are used as initial 
guesses. The second recommendation would be to use the regression coefficients 
obtained in the first approach for initial “guesses” of the coefficients in the second 
approach. ConClusions: Parameter estimation for the Markov process within 
decision-analytic Markov models can be obtained from separate sources, but we 
recommend fitting Markov models to one source of longitudinal data. The output for 
the parameter estimates varied between the approaches used, and while msm is a 
useful tool for parameter estimation, it requires reasonable initial approximations.
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do diffeRent Modeling teChniques Change Rankings of hosPital 
PeRfoRManCe? : Multilevel Modeling vs. standaRd logistiC 
RegRession
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objeCtives: There are conflicting results about whether using multilevel mod-
eling (MLM) produces different rankings in hospital performance compared 
to using traditional statistical techniques. We would like to compare hospital 
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tasis. The 1- and 5-year post-hepatic transplantation survival rates among patients 
subjected to bone scintigraphy were 81% and 69%, respectively; those among patients 
not subjected to scintigraphy were 78% and 62%, respectively (p = 0.25). The 1- and 
5-year post-HTx recurrence rates among patients subjected to bone scintigraphy were 
4.8% and 10.7%; those among patients not subjected to scintigraphy were 2.9% and 
10.1%, respectively (p = 0.46). Results: The cost generated by the current evaluation 
policies, US$ 27.582, did not result in the detection of any sub-clinical metastasis and 
therefore failed to provide positive cost-effectiveness. ConClusions: Clinical evi-
dence has demonstrated that bone scintigraphy did not provide aditional information 
about patient selection since the incidence of metastasis in early stages is very low. 
In our cohort, the use of scintigraphy in the assessment of patients with early stages 
of HCC and within the Milão criteria, included in a liver transplant list by dead donor, 
in a center in the south of Brazil, had zero benefit.
PRM25
Cost-utility evaluation of Continuing eduCation foR the 
ManageMent of tyPe 2 diabetes Mellitus useRs in PeRnaMbuCo – 
bRazil
Aquino C.M.1, Lima R.C.2, Bezerra A.F.2, Sousa I.M.3, Cesse E.Â.3, Carvalho E.M.2, Fontbonne A.4
1Federal University of Pernambuco, Recife, Brazil, 2Federal University of Pernambuco, Recife, 
Brazil, 3Oswaldo Cruz Foundation - Fiocruz, Recife, Brazil, 4Institut de Recherche pour le 
Développement, Marseille, France
objeCtives: To determine the cost-utility of continuing education for the man-
agement of patients with type 2 Diabetes Mellitus (T2DM), in Pernambuco - 
Brazil. Methods: It’s a cost-utility evaluation, using the Markov model to simulate 
the results in health scenarios, from the perspective of the health system. It was 
considered an analytic horizon of 20 years and selected the category of direct medi-
cal costs. Data were obtained from primary source, SERVIDIAH study, and secondary 
sources from health information systems and literature. The reference scenario 
represents the standard health care management performed in public health ser-
vices. The simulated scenarios for post-intervention’s results were based on the 
suggestion of consulted experts in regard the effectiveness of continuing education 
for health professionals in primary health care (PHC) for the patient’s complications 
reduction. Results: The average individual, representative Pernambuco’s popula-
tion, was female, 61 years old and diagnosed with T2DM for 8.7 years. These and 
other clinical characteristics that influence the calculation of the transition prob-
abilities were gathered from over 800 patients with T2DM from Pernambuco. For the 
reference scenario, the cost for one individual was calculated for the intervention’s 
first year, 2011: without complications (U$ 491.04), with microvascular complications 
(U$ 774.23), macrovascular complications (U$ 1,945.95) and both complications (U$ 
2,229.14). The incremental cost for the implementation of the intervention was 
U$ 242.42 per individual/year, later added to the cost for standard management 
in the post-intervention scenarios. At the cost-utility evaluation, only the first 
simulated scenario (Very Satisfactory Result) was cost-effective, with Incremental 
Cost-effectiveness Ratio (ICER) of U$ 7,362.70/QALY. ConClusions: The ICER pre-
sented suggests that the intervention isn’t a cost-effective alternative. Given the 
uncertainties about the effectiveness of continuing education for professionals in 
the PHC on the health of users, it is necessary to conduct in-depth studies on the 
association between these variables.
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objeCtives: To critically appraise published pharmacoeconomic studies of 
two novel antiplatelet (AP) agents (ticagrelor and prasugrel) in the treatment 
of acute coronary syndromes (ACS). Methods: Key terms related to economic 
evaluations of ticagrelor and/or prasugrel were searched in EMBASE, MEDLINE and 
International Pharmaceutical Abstracts. English-language articles evaluating the 
use of these agents in adults with ACS were included. Studies assessing genotyp-
ing-guided treatments were excluded. Elements of each study were independently 
extracted based on the ISPOR Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) checklist by two reviewers. Results: Eleven (7 ticagrelor, 4 
prasugrel) studies were identified, 7 of which included both cost-effectiveness 
and cost-utility analysis. No comparisons were made between prasugrel and 
ticagrelor and each agent was compared to clopidogrel. The manufacturer of the 
novel AP funded all but one study. Most models were Markov-based simulations, 
with almost all studies adopting a healthcare system perspective and lifetime 
time horizon. Two randomized-control trials (RCTs), PLATO and TRITON-TIMI 38 
were most commonly cited for ticagrelor and prasugrel, respectively, with few 
non-RCTs used for clinical data input. While methods to derive the efficacy data 
were commonly reported, utility estimates varied for some health states between 
studies using the same data by the same sponsor. Both ticagrelor and prasugrel 
were deemed cost-effective vs. clopidogrel in base-case analyses. ConClusions: 
Studies would benefit from greater consistency in sources of costing data and 
estimates of utility values and decrements. There is a clear reliance on single mul-
tinational RCTs as the primary data source for the vast majority of model inputs, 
and the PLATO study has been heavily criticized for issues related to external 
validity. More independent, non-industry sponsored economic evaluations and 
real-world clinical data are required in the future. Reporting checklists do not 
capture these latent issues behind economic evaluations, as identified by our 
appraisal of the literature.
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further investigation as a way to detect, characterize, and address bias in retrospec-
tive samples.
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objeCtives: In clinical trials of early-stage prostate cancer, demonstration of an 
overall survival (OS) benefit is challenging because of prolonged patient survival. 
While the development of metastasis is a major milestone in the disease, payers 
are interested in understanding the clinical relevance of metastatic-free survival 
(MFS) as a surrogate endpoint and its relationship with long-term outcomes, in 
particular, OS. The objective of the current study was to identify empirical evi-
dence evaluating MFS in patients with prostate cancer. Methods: A structured 
literature review was conducted in PubMed (1999−2014) to identify clinical trials in 
prostate cancer using MFS as a primary endpoint, and clinical and observational 
studies that evaluated the association between MFS and OS. Results: Three 
published clinical trials used MFS as a primary endpoint. The studies employed 
varying definitions for MFS (e.g., bone metastasis only or bone and soft tissue 
metastasis). In one long-term study comparing adjuvant radiotherapy to usual 
care, both MFS and OS outcomes were significantly improved with radiotherapy, 
suggesting a relationship between these two endpoints. Four additional studies 
examined the association between MFS and OS. One study reported that dis-
tant metastasis at three years met the Prentice criteria for surrogacy of prostate 
cancer-specific survival at 10 years. A second study reported that MFS was one of 
four independent prognostic variables for OS in prostate cancer. The remaining 
two studies demonstrated that time to metastasis was significantly associated 
with prostate cancer-specific mortality. ConClusions: MFS has been used as 
the primary endpoint in several prostate cancer studies, providing support for the 
clinical relevance of this outcome. Current evidence from the literature suggests 
an association between MFS and OS, however additional research is needed to 
further investigate this relationship.
ReseaRCh on Methods – Cost Methods
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objeCtives: The IMS CORE Diabetes Model (CDM) is a widely published and 
validated decision support tool. The model uses UKPDS68 and UKPDS82 risk 
equations (REs) to predict events and has been updated to include REs from the 
Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-Risk-Engine 
(A-RE). The objective of this study was to compare and contrast cardiovascular 
(CV) incidence and cost-effectiveness (CE) across these four REs. Methods: 
Lifetime analyses comparing the CE of metformin+ sulphonylurea (M+S) versus 
metformin + DPP-4 (M+D) was undertaken using the CDM. Basal insulin rescue 
therapy (BI) was applied to both arms at HbA1c threshold levels of 7.5%. Efficacy 
data for dual therapy was sourced from a published mixed treatment compari-
son; HbA1c and BMI change at one-year of -0.8% and 0.199kg/m2 (M+D);-0.79% 
and 0.707kg/m2 (M+S) and -0.82 and 0.545 kg/m2 (BI), respectively, were applied. 
Hypoglycemia rates were taken from the same systematic review. US 2012 costs 
were used and discounting was applied at 3.0%. Results: In the base analysis 
(UKPDS68) predicted CV incidence for myocardial infarction, stroke, ischemic 
heart disease and heart failure was 31.42%, 15.59%, 12.85% and 21.01%, respec-
tively, for patients treated with M+D and 31.39% , 15.23%, 12.51% and 21.26% for 
patients treated with M+S. This compared to 26.72%, 14.31%, 17.96% and 12.74% 
(M+D) and 26.02%, 13.94%, 17.91% and 13.43% (M+S) using UKPDS82 REs; 30.19%, 
52.93%, 6.42% and 6.22% (M+D) and 29.7%, 53.98%, 6.23% and 6.5% (M+S) using 
S-NDR REs and 42.62%, 15.05%, 11.98% and 19.56% (M+D) and 42.17%, 15.1%, 
11.97% and 20.46% (M+S) using A-RE REs. Incremental cost per quality adjusted 
life years were estimated at $78,537 (UKPDS68); $77,594 (UKPDS82); $70,054 
(S-NDR) and $74,783 (A-RE). ConClusions: There was a noteworthy difference 
in predicted CV incidence across the four equations; however, CE results were 
relatively stable. Consequently, choice of RE appears unlikely to significantly 
impact CE.
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objeCtives: Evaluate for the first time in Brazil the pertinence of systematically 
requesting whole-body bone scintigraphy in early-stage HCC adult patients as a 
requisite for inclusion on the waiting list for HTx from a deceased donor, according 
to a reference center in South Brazil. Current pre-transplantation evaluation policy 
includes mandatory bone scintigraphy as a requisite for selecting patients to be 
included on hepatic transplantation list. Previous studies, however, have shown that 
routine scintigraphy is not cost-effective and generates unnecessary Health System 
costs. Methods: We retrospectively analyzed 256 medical files of early-stage HCC 
patients who underwent hepatic transplantation, 187 of whom were subjected to 
pre-transplantation bone scintigraphy. The most common etiology was hepatitis C 
viral infection, the most common liver functional class was Child B, and 78% of the 
patients met the Milan criteria. None of the 187 scintigraphies was positive for metas-
